A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-05-31
Adverse events
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-06-18 (study day 11); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-12 (study day 188); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-05 (study day 212); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-08 (study day 366); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-14 (study day 372); relationship: not assessed
Data queries
No data queries.